{"output": [["Allergan Plc", "COMP", "See", "2018 GAAP Net Revenue", "ECON_INDICATOR"], ["Allergan Plc", "COMP", "See", "2018 GAAP Performance Loss Per Share", "ECON_INDICATOR"], ["Allergan Plc", "COMP", "See", "2018 Non-GAAP Performance Earnings Per Share", "ECON_INDICATOR"], ["Allergan Plc", "COMP", "Plan", "Sell Remaining Position in Teva", "COMP"], ["Allergan Plc", "COMP", "Has", "Prudently Divest", "SECTOR", "Relate_To", "Securities of Teva", "COMP"], ["Allergan Plc", "COMP", "Anticipates", "Future Impact of Tax Cut and Jobs Act", "CONCEPT", "Impact_On", "CO\u2018s Non-GAAP Effective Tax Rate", "ECON_INDICATOR"], ["Allergan Plc", "COMP", "Sees", "No Generic Entry for Restasis Prior to Q2 2018", "EVENT"], ["Allergan Plc", "COMP", "Sees", "Ongoing Cost Reductions of $300 Million \u2013 $400 Million in 2018", "ECON_INDICATOR", "From", "Fiscal 2017 Non-GAAP Operating Expenses", "ECON_INDICATOR"], ["Allergan Plc", "COMP", "Faces", "Loss of Exclusivity Revenue Headwinds in 2018", "CONCEPT"]], "published": "2018-01-08T23:46:00.000+02:00"}